Rare Antierythrocyte Antibodies as a Cause of Post-Transfusion Hemolytic Complications

Abstract

The relevance of measures to ensure immunological safety of transfusion therapy in a medical organization is demonstrated. The main purpose of the study was to analyze the results of establishing the specificity of alloimmune anti-erythrocyte antibodies in recipients, as well as to compile a priority scale for transfusion-dangerous antigens in the Perm region. The materials for the study were the results of the determination and identification of alloimmune anti-erythrocyte antibodies in recipients of the Perm region for the period 2022–2024. Research results. The study made it possible to establish a priority scale for transfusion-dangerous antigens in the Perm region. It was shown that some of the erythrocyte antigens that are not included in the mandatory list of studies in the recipient are highly immunogenic and can cause the development of post-transfusion hemolytic complications. Attention should be paid to the validity of transfusion of erythrocyte-containing blood components, repeated screening of alloimmune antibodies in recipients, as well as training of doctors involved in the clinical use of donor blood components on issues of transfusiology and immunohematology. The case of the development of a hemolytic post-transfusion complication is considered, the probable causes of its occurrence are proposed, attention is drawn to the data of immunohematological studies and the necessary preventive measures.